29.40 0.00 (0.00%)
After hours: 4:16PM EDT
|Bid||29.05 x 4000|
|Ask||29.65 x 2200|
|Day's Range||28.05 - 30.00|
|52 Week Range||11.85 - 30.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.60|
While the Dow reclaimed its above 25,000 levels after almost a month Nasdaq is at a record high. The Dow Jones Industrial Average gained 0.38 percent to close at 25,019.41, while the S&P 500 Index increased 0.11 percent to close at 2,801.31. The Nasdaq Composite Index climbed 0.03 percent to close at 7,825.98.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding MNTA totaled $198 million.
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...
LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ZTS sign up now at www.wallstequities.com/registration. Under evaluation this morning are these four stocks: Flexion Therapeutics Inc. (NASDAQ: FLXN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), PetIQ Inc. (NASDAQ: PETQ), and Zoetis Inc. (NYSE: ZTS).
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Index (PMI) data, output in the Healthcare sector is rising.
Momenta Pharmaceuticals, Inc. (MNTA), today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, June 13, 2018 at 2:40 P.M. PT/5:40 P.M. ET. A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event. Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
CAMBRIDGE, Mass., May 17, 2018-- Momenta Pharmaceuticals, Inc. today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and the discovery of M281. The presentation ...
In the North America region, Teva registered Copaxone sales of $476 million, representing a YoY (year-over-year) decline of 40% due to increased competition from generics in the United States where the Copaxone sales were $462 million in fiscal 1Q18. In Europe, Copaxone sales registered growth of ~1% to $153 million. In the Growth Market segment, Copaxone sales came in at $16 million, a YoY decline of 24%.
Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.
Momenta Pharmaceuticals, Inc. (MNTA) today reported its financial results for the first quarter ended March 31, 2018 and provided a corporate update. “We made important progress in the first quarter of 2018 across our complex generic, biosimilar and novel drug portfolios. Importantly, Glatopa 40 mg/mL received FDA approval and, with Sandoz’s commercial launch now underway, we look forward to the potential for accelerated adoption by customers as the year progresses.
NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 8, 2018 at 8:00 AM Eastern ...
Westphal has a long track record of co-founding successful drug developers, including Alnylam Pharmaceuticals and Momenta Pharmaceuticals.
CAMBRIDGE, Mass., May 01, 2018-- Momenta Pharmaceuticals, Inc., today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before ...
NEW YORK, April 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Momenta Pharmaceuticals Inc’s (NASDAQ:MNTA): Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. TheRead More...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Over the last one-month, outflows of investor capital in ETFs holding MNTA totaled $1.01 billion.